Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
A New Chapter in Survival! A Quadruple Drug Combination Opens Up a New Treatment Pathway for Multiple Myeloma Patients
🌟 *A New Chapter in Survival! A Quadruple Drug Combination Opens Up a New Treatment Pathway for Multiple Myeloma Patients.* 🌟
💪Multiple myeloma has long been a challenging disease to treat, but with the development of new drugs and immunotherapy, the prognosis for MM patients has improved significantly. Now, a new study has opened up a fresh avenue of treatment for us!
#NEJM, #Multiple myeloma
🔬 **Research Findings**
According to a report in the New England Journal of Medicine (NEJM), a study has demonstrated that daratumumab, targeting the CD38 molecule, combined with VRd (referred to as the D-VRd regimen), shows promising safety and efficacy for newly diagnosed multiple myeloma patients eligible for transplantation (NDMM).
📊 **Study Results**
After a median follow-up of 47.5 months, the D-VRd group had a lower risk of disease progression or death compared to the VRd group. At 48 months, the progression-free survival rate for the D-VRd group reached 84.3%, significantly higher than the 67.7% in the VRd group (P＜0.001). Additionally, the D-VRd group had significantly higher rates of complete response and deeper response compared to the VRd group, with a higher MRD negativity rate as well.
💡 **Conclusion**
This study indicates that the D-VRd regimen brings significant benefits to newly diagnosed multiple myeloma patients, including prolonged progression-free survival, higher rates of response, and MRD negativity. This combined therapy has the potential to become a new frontline treatment for multiple myeloma, offering patients longer survival and improved quality of life!
🔍 **Learn More**
For more information on the latest treatment advances and research findings in multiple myeloma, stay tuned to our page!
📚We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070
#MultipleMyeloma #NewTreatmentApproach #HealthScience #MedicalResearch